Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

The prevalence of obesity in India was lower than in other countries but now it's increasing, Rachel Batterham, senior vice ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

Wake up with Breakfast news in your inbox every market ... which features plenty of investigational drugs beyond Eli Lilly's core area of diabetes and obesity. Even with Eli Lilly's Mounjaro ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Cramer discussed Eli Lilly’s (NYSE:LLY) stock drop, noting that the company had projected $58 to $61 billion in revenue for the coming year, driven by its GLP-1 drugs for diabetes, weight loss ...

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

Eli Lilly has followed Novo ... strong future demand for diabetes and obesity drugs. The pharma group confirmed it is planning to spend $2.5 billion on a new facility in Alzey, Germany, that ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.